248 related articles for article (PubMed ID: 10084288)
21. Maintenance therapy with intravenous iron in hemodialysis patients receiving erythropoietin.
Kotaki M; Uday K; Henriquez M; Blum S; Dave M
Clin Nephrol; 1997 Jul; 48(1):63-4. PubMed ID: 9247787
[No Abstract] [Full Text] [Related]
22. The comparative short-term effectiveness of iron dosing and formulations in US hemodialysis patients.
Kshirsagar AV; Freburger JK; Ellis AR; Wang L; Winkelmayer WC; Brookhart MA
Am J Med; 2013 Jun; 126(6):541.e1-541.e14. PubMed ID: 23597800
[TBL] [Abstract][Full Text] [Related]
23. Iron supplementation in haemodialysis--practical clinical guidelines.
Silva J; Andrade S; Ventura H; Santos JP; Colaço S; Oliveira C; Ponce P
Nephrol Dial Transplant; 1998 Oct; 13(10):2572-7. PubMed ID: 9794562
[TBL] [Abstract][Full Text] [Related]
24. Is there a role for adjuvant therapy in patients being treated with epoetin?
Hörl WH
Nephrol Dial Transplant; 1999; 14 Suppl 2():50-60. PubMed ID: 10334668
[TBL] [Abstract][Full Text] [Related]
25. Intravenous iron treatment in paediatric chronic kidney disease patients not on erythropoietin.
Morgan HE; Holt RC; Jones CA; Judd BA
Pediatr Nephrol; 2007 Nov; 22(11):1963-5. PubMed ID: 17704954
[TBL] [Abstract][Full Text] [Related]
26. Association between transferrin receptor-ferritin index and conventional measures of iron responsiveness in hemodialysis patients.
Chen YC; Hung SC; Tarng DC
Am J Kidney Dis; 2006 Jun; 47(6):1036-44. PubMed ID: 16731299
[TBL] [Abstract][Full Text] [Related]
27. The efficacy and safety of current intravenous iron preparations for the management of iron-deficiency anaemia: a review.
Qunibi WY
Arzneimittelforschung; 2010; 60(6a):399-412. PubMed ID: 20648931
[TBL] [Abstract][Full Text] [Related]
28. Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study.
Coyne DW; Kapoian T; Suki W; Singh AK; Moran JE; Dahl NV; Rizkala AR;
J Am Soc Nephrol; 2007 Mar; 18(3):975-84. PubMed ID: 17267740
[TBL] [Abstract][Full Text] [Related]
29. Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation.
Fishbane S; Frei GL; Maesaka J
Am J Kidney Dis; 1995 Jul; 26(1):41-6. PubMed ID: 7611266
[TBL] [Abstract][Full Text] [Related]
30. Safety aspects of parenteral iron in patients with end-stage renal disease.
Sunder-Plassmann G; Hörl WH
Drug Saf; 1997 Oct; 17(4):241-50. PubMed ID: 9352960
[TBL] [Abstract][Full Text] [Related]
31. Percentage of hypochromic red blood cells as predictor of erythropoietic and iron response after i.v. iron supplementation in maintenance haemodialysis patients.
Braun J; Lindner K; Schreiber M; Heidler RA; Hörl WH
Nephrol Dial Transplant; 1997 Jun; 12(6):1173-81. PubMed ID: 9198047
[TBL] [Abstract][Full Text] [Related]
32. New Options for Iron Supplementation in Maintenance Hemodialysis Patients.
Vaziri ND; Kalantar-Zadeh K; Wish JB
Am J Kidney Dis; 2016 Mar; 67(3):367-75. PubMed ID: 26616335
[TBL] [Abstract][Full Text] [Related]
33. The management of iron metabolism in recombinant human erythropoietin treated dialysis patients by Dutch nephrologists.
Kooistra MP; Marx JJ
Nephrol Dial Transplant; 1997 May; 12(5):879-83. PubMed ID: 9175038
[TBL] [Abstract][Full Text] [Related]
34. Neutrophil impairment associated with iron therapy in hemodialysis patients with functional iron deficiency.
Patruta SI; Edlinger R; Sunder-Plassmann G; Hörl WH
J Am Soc Nephrol; 1998 Apr; 9(4):655-63. PubMed ID: 9555668
[TBL] [Abstract][Full Text] [Related]
35. Cost-effectiveness impact of iron dextran on hemodialysis patients' use of epoetin alfa and blood.
Driver PS
Am J Health Syst Pharm; 1998 Dec; 55(24 Suppl 4):S12-6. PubMed ID: 9872688
[TBL] [Abstract][Full Text] [Related]
36. Management of early renal anaemia: diagnostic work-up, iron therapy, epoetin therapy.
Van Wyck DB
Nephrol Dial Transplant; 2000; 15 Suppl 3():36-9. PubMed ID: 11032356
[TBL] [Abstract][Full Text] [Related]
37. [Guidelines for the treatment of anemia in chronic renal failure].
Triolo G;
G Ital Nefrol; 2003; 20 Suppl 24():S61-82. PubMed ID: 14666504
[TBL] [Abstract][Full Text] [Related]
38. Beneficial effects of iron therapy in renal failure patients on hemodialysis.
Fishbane S; Mittal SK; Maesaka JK
Kidney Int Suppl; 1999 Mar; 69():S67-70. PubMed ID: 10084289
[TBL] [Abstract][Full Text] [Related]
39. Australian haemodialysis patients on intravenous epoetin alfa or intravenous darbepoetin alfa: how do they compare?
Pussell BA; Walker R;
Nephrology (Carlton); 2007 Apr; 12(2):126-9. PubMed ID: 17371333
[TBL] [Abstract][Full Text] [Related]
40. Reticulocyte hemoglobin content predicts functional iron deficiency in hemodialysis patients receiving rHuEPO.
Mittman N; Sreedhara R; Mushnick R; Chattopadhyay J; Zelmanovic D; Vaseghi M; Avram MM
Am J Kidney Dis; 1997 Dec; 30(6):912-22. PubMed ID: 9398141
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
